سعر ميرابلاد إكس آر 25 مجم أقراص مغلفة ممتدة المفعول 2022

Mirabegron 25 mg prolonged-release film-coated tablets, pack of 10, by Rameda (Egypt), for overactive bladder.

• Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.Population: AdultsMedicines.org.uk (eMC) / MHRA
• Treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years (UK SmPC licence; confirm Egyptian paediatric licence before use).Population: Paediatric 3 to <18 years (NDO)Medicines.org.uk (eMC) / MHRA

• Common: urinary tract infection, tachycardia, headache, dizziness, nausea, constipation, diarrhoea. Uncommon: atrial fibrillation, palpitations, rash, pruritus, blood pressure increased. Rare/post-marketing: urinary retention, angioedema, hypertensive crisis.International label, same formulation · Medicines.org.uk (eMC) / MHRA

• Hypersensitivity to mirabegron or any excipient. Severe uncontrolled hypertension (systolic ≥180 mmHg and/or diastolic ≥110 mmHg).International label, same formulation · Medicines.org.uk (eMC) / MHRA

• Mirabegron can increase blood pressure; measure BP at baseline and periodically, especially in hypertensive patients.International label, same formulation · Medicines.org.uk (eMC) / MHRA
• Not recommended in ESRD, dialysis, or severe hepatic impairment. Caution in bladder outlet obstruction and with concomitant antimuscarinics for OAB (urinary retention reported).International label, same formulation · Medicines.org.uk (eMC) / MHRA
• Caution in patients with known QT prolongation or taking QT-prolonging medicines (effects unknown in these populations).International label, same formulation · Medicines.org.uk (eMC) / MHRA

• Strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin)ModerateIncrease mirabegron exposure; use max 25 mg in mild–moderate renal or mild hepatic impairment; avoid in severe renal or moderate hepatic impairment with these inhibitors.Medicines.org.uk (eMC) / MHRA
• CYP2D6 substrates with narrow therapeutic index (e.g. thioridazine, flecainide, propafenone, imipramine, desipramine)ModerateMirabegron is a moderate CYP2D6 inhibitor; caution and consider dose adjustment of the substrate.Medicines.org.uk (eMC) / MHRA
• Digoxin (P-gp substrate)ModerateMirabegron increases digoxin Cmax/AUC modestly; start digoxin at the lowest dose and titrate with serum monitoring when initiating combination.Medicines.org.uk (eMC) / MHRA

• Not recommended during pregnancy. Limited human data; animal studies showed reproductive toxicity at high exposures.International label, same formulation · Medicines.org.uk (eMC) / MHRA
• Should not be used during breast-feeding; mirabegron is excreted in rodent milk and is predicted in human milk.International label, same formulation · Medicines.org.uk (eMC) / MHRA

• Mirabegron: Beta-3 adrenergic receptor agonist relaxing the detrusor smooth muscle during bladder filling, increasing bladder capacity.